Silverstein Zach, Alva Mantari Alicia, Breglio Kimberly, Pajuelo Monica J, Valdiviezo Gladys, Cruz Sandra, Castañeda Pamela, Rothstein Jessica D, Huaman-Fernandez Lucia, Cabrera Lilia, Salguedo Mario, Barrientos Franklin, Saldivar-Espinoza Bryan, Núñez-Fernández Dennis, Gilman Robert H, Sheen Patricia, Roman-Gonzalez Avid, Noazin Sassan, Zimic Mirko
Department of International Health, Johns Hopkins School of Public Health, Baltimore, Maryland.
Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
Am J Trop Med Hyg. 2024 Dec 10;112(3):685-691. doi: 10.4269/ajtmh.24-0494. Print 2025 Mar 5.
As many as one in three people worldwide have anemia, with young children at increased risk of both disease and complications. In settings without clinical laboratories, portable hemoglobinometers serve important roles in diagnosing anemia and estimating prevalence. Here, we assess the validity of two such point-of-care devices-the HemoCue Hb201 and the HemoCue Hb301-relative to the international reference standard, the cyanmethemoglobin method. In total, 428 children ages 6-60 months were recruited at health posts in Lima, Peru, and venous and capillary blood samples were collected from each participant. Venous blood was assessed with the cyanmethemoglobin method, whereas capillary blood was assessed using the Hb201 and the Hb301; 16.1% of participants were found to have anemia using the cyanmethemoglobin method. Both the Hb201 (43.7%) and the Hb301 (20.6%) overestimated this prevalence, with the former reaching statistical significance (P <0.0001 and P = 0.11, respectively). Both devices also tended to underestimate hemoglobin concentration, with the Hb201 (mean difference = -0.99 g/dL; percentage error = -8.1%) being appreciably less accurate than the Hb301 (mean difference = -0.35 g/dL; percentage error = -2.7%). Areas under the curve for the Hb201 (0.92) and the Hb301 (0.93) were statistically similar (P = 0.28); however, the Hb201 incorrectly classified 29.4% of participants compared with 11.0% for the Hb301. Both devices had more false positives than false negatives. In conclusion, the Hb301 was found to be significantly more accurate than the Hb201 at measuring hemoglobin, diagnosing anemia, and estimating anemia prevalence.
全球多达三分之一的人患有贫血症,幼儿患这种疾病和出现并发症的风险更高。在没有临床实验室的环境中,便携式血红蛋白仪在诊断贫血症和估计患病率方面发挥着重要作用。在此,我们评估了两种即时检测设备——HemoCue Hb201和HemoCue Hb301相对于国际参考标准氰化高铁血红蛋白法的有效性。总共在秘鲁利马的卫生站招募了428名6至60个月大的儿童,并从每个参与者身上采集了静脉血和毛细血管血样本。静脉血采用氰化高铁血红蛋白法进行评估,而毛细血管血则使用Hb201和Hb301进行评估;使用氰化高铁血红蛋白法发现16.1%的参与者患有贫血症。Hb201(43.7%)和Hb301(20.6%)都高估了这一患病率,前者达到统计学显著性(P分别<0.0001和P = 0.11)。两种设备也都倾向于低估血红蛋白浓度,Hb201(平均差异=-0.99 g/dL;百分比误差=-8.1%)的准确性明显低于Hb301(平均差异=-0.35 g/dL;百分比误差=-2.7%)。Hb201(0.92)和Hb301(0.93)的曲线下面积在统计学上相似(P = 0.28);然而,Hb201错误分类了29.4%的参与者,而Hb301为11.0%。两种设备的假阳性都比假阴性多。总之,发现在测量血红蛋白、诊断贫血症和估计贫血症患病率方面,Hb301比Hb201明显更准确。